Authors: Martha Powell, Future Science Group
A novel MERS vaccine was demonstrated to be safe, well-tolerated and immunogenic in a Phase I, first-in-human trial.
The trial, published in the Lancet Infectious Disease, evaluated GeneOne Life Science Inc. (South Korea) and Inovio Pharmaceuticals’ (PA, USA) DNA vaccine, GLS-5300, and was the first MERS vaccine to be tested in humans – previous candidates have been assessed in camels.
The team enrolled 75 volunteers who received one of three dosages of the vaccine in conjunction with an electrical impulse across three time points – initial, 1 month and 3 months. The participants were then followed for a year post-vaccination and compared with individuals who had recovered from natural MERS infection.